Inventor
GAI YONGHUA
US39 patents
⚠️ This page may combine multiple inventors who share the name “GAI YONGHUA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ENANTA PHARM INC
16 patentsUS7635683B2Dec 22, 2009
Quinoxalinyl tripeptide hepatitis C virus inhibitors
ENANTA PHARM INC75 citations98
US7687459B2Mar 30, 2010
Arylalkoxyl hepatitis C virus protease inhibitors
ENANTA PHARM INC26 citations93
US7605126B2Oct 20, 2009
Acylaminoheteroaryl hepatitis C virus protease inhibitors
ENANTA PHARM INC38 citations92
US8372802B2Feb 12, 2013
Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
ENANTA PHARM INC12 citations84
US7384921B2Jun 10, 2008
Polymorphic forms of 6-11 bicyclic ketolide derivatives
ENANTA PHARM INC11 citations84
US7229972B2Jun 12, 2007
3,6-Bicyclolides
ENANTA PHARM INC15 citations84
US7291602B2Nov 6, 2007
11,12-lactone bicyclolides
ENANTA PHARM INC9 citations74
US7563877B2Jul 21, 2009
Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182
ENANTA PHARM INC2 citations63
US7517859B2Apr 14, 2009
Spirocyclic bicyclolides
ENANTA PHARM INC2 citations63
US7419962B2Sep 2, 2008
3,6-bicyclolides
ENANTA PHARM INC3 citations63
US8951998B2Feb 10, 2015
Quinoxaline-containing compounds as hepatitis C virus inhibitors
ENANTA PHARM INC0 citations52
US8377872B2Feb 19, 2013
Cyclic P3 tripeptide hepatitis C serine protease inhibitors
ENANTA PHARM INC2 citations52
US7910587B2Mar 22, 2011
Quinoxalinyl dipeptide hepatitis C virus inhibitors
ENANTA PHARM INC2 citations52
US7312201B2Dec 25, 2007
Tetracyclic bicyclolides
ENANTA PHARM INC2 citations52
US9493506B2Nov 15, 2016
Macrocyclic hepatitis C serine protease inhibitors
ENANTA PHARM INC0 citations48
US8361958B2Jan 29, 2013
Oximyl HCV serine protease inhibitors
ENANTA PHARM INC0 citations42
GAI YONGHUA
8 patentsUS8211891B2Jul 3, 2012
Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
GAI YONGHUA4 citations62
US8936781B2Jan 20, 2015
Macrocyclic compounds as hepatitis C virus inhibitors
GAI YONGHUA1 citations51
US8324155B2Dec 4, 2012
Quinoxaline-containing compounds as hepatitis C virus inhibitors
GAI YONGHUA1 citations51
US9193740B2Nov 24, 2015
Bismacrocyclic compounds as hepatitis C virus inhibitors
GAI YONGHUA0 citations41
US8940688B2Jan 27, 2015
Fluorinated tripeptide HCV serine protease inhibitors
GAI YONGHUA0 citations41
US8501682B2Aug 6, 2013
Difluorinated tripeptides as HCV serine protease inhibitors
GAI YONGHUA0 citations41
US8273709B2Sep 25, 2012
Triazole-containing macrocyclic HCV serine protease inhibitors
GAI YONGHUA0 citations41
US8101567B2Jan 24, 2012
Heteroaryl-containing tripeptide HCV serine protease inhibitors
GAI YONGHUA0 citations41
BRISTOL MYERS SQUIBB CO
6 patentsUS7300936B2Nov 27, 2007
α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors
BRISTOL MYERS SQUIBB CO46 citations94
US6414179B1Jul 2, 2002
Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors
BRISTOL MYERS SQUIBB CO32 citations92
US6350892B1Feb 26, 2002
Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
BRISTOL MYERS SQUIBB CO41 citations92
US6255496B1Jul 3, 2001
Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
BRISTOL MYERS SQUIBB CO15 citations83
US7786122B2Aug 31, 2010
α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors
BRISTOL MYERS SQUIBB CO12 citations82
US6492550B2Dec 10, 2002
Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors
BRISTOL MYERS SQUIBB CO1 citations51